EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Model-based assessment of VRC07-523LS dosing in infants through population pharmacokinetic -pharmacodynamic modelling in adults and infants

Dustin Huynh, Mina Nikanjam, Coleen K Cunningham, Elizabeth J McFarland, Petronella Muresan, Charlotte Perlowski, Dwight E Yin iD, Jack Moye, Hans Spiegel, Lucio Gama, Martin Gaudinski, Edmund V Capparelli

Journal of Antimicrobial Chemotherapy · 2026

DOI: 10.1093/jac/dkaf449 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Antimicrobial Chemotherapy, 2026. Verfasst von Dustin Huynh und 11 weiteren Autor:innen. Beteiligte Einrichtung: Schools of Medicine and Skaggs School of Pharmacy, UC San Diego, La Jolla, CA 92093, USA. Hauptthemen laut MEDLINE: HIV Infections, HIV Antibodies, Anti-HIV Agents. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 22 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: NIH HHS, National Institute of Allergy and Infectious Diseases, NIMH NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objectives

To develop a population pharmacokinetic (popPK) model to understand factors affecting the broadly neutralizing HIV antibody (bNAb) VR07-523LS disposition and infant predicted serum neutralization 80% inhibitory dilution titre ratio (PT80) and its potential relationship to antiviral effects.

Methods

PK data from two studies were used: infants exposed to HIV initiating therapy ≤5 days of age (IMPAACT P1112, n = 21) and healthy adults (VRC605, n = 25). The infant study implemented fixed subcutaneous (s.c.) dosing whereas the adult study implemented weight-based dosing, via both intravenous (i.v.) and s.c. routes. Monte Carlo simulation assessed two doses (80 mg followed by 100 mg at 12 weeks) to determine the maintenance of levels >10 µg/mL in virtual infants. The broadly neutralizing antibodies (bNAbs) concentration/IC80 ratio (PT80) was calculated on the basis of simulated concentrations from the popPK model and VRC07-523LS HIV-1 sensitivity (IC80) distribution.

Results

This model predicts typical infant CL/F and t1/2 of 159 mL/day/70 kg and 39 days. Comparatively, predicted adult typical CL/F and t1/2 were 269 mL/day/70 kg and 31 days. Concentrations were >10 µg/mL in >87% of virtual infants at 12 weeks following one dose and >98% at 24 weeks following two doses. Median (90% predictive interval) PT80 was 163 (71–383), 116 (51–274) and 61 (26–144) at 6, 8 and 12 weeks, respectively. Significant model covariates included age (infant versus adult) and multiple dosing.

Conclusions

Age and repeat dosing influence VRC07-523LS PK. An 80-mg dose followed by 100 mg at 12 weeks rapidly achieves and maintains concentrations >10 µg/mL for >24 weeks. This dosing strategy is expected to result in antiviral effects in patients with sensitive viruses and supports further evaluation of VRC07-523LS.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

HIV InfectionsHIV AntibodiesAnti-HIV AgentsHumansInfantAdultFemaleMaleMonte Carlo MethodInfant, NewbornHIV-1Antibodies, NeutralizingYoung AdultBroadly Neutralizing AntibodiesInjections, Subcutaneous

Substanzen

HIV AntibodiesAnti-HIV AgentsAntibodies, NeutralizingBroadly Neutralizing Antibodies

Autor:innen und Institutionen

  • Schools of Medicine and Skaggs School of Pharmacy, UC San Diego, La Jolla, CA 92093, USA.
  • School of Medicine, UC Irvine, Irvine CA and Children's Hospital of Orange County, Orange, CA 92868, USA.
  • Pediatric Infectious Diseases, University of Colorado School of Medicine, Aurora, CO 80045, USA.
  • Statistical and Data Management Center (SDMC), Frontier Science Foundation, Boston, MA 02115, USA.
  • FHI 360, Durham, NC 27701, USA.
  • Division of AIDS, National Institute of Allergy and Infectious Diseases, Bethesda, MD 20892, USA.

ORCID-Profile: Dwight E Yin

Förderung

  • NIH HHS
  • National Institute of Allergy and Infectious Diseases
  • NIMH NIH HHS
  • NIAID NIH HHS
  • Eunice Kennedy Shriver National Institute of Child Health and Human Development
  • International Maternal Pediatric Adolescent AIDS Clinical Trials Network
  • National Institute of Mental Health
  • National Institutes of Health

Zitieren

APA

Huynh, D., Nikanjam, M., Cunningham, C. K., McFarland, E. J., Muresan, P., Perlowski, C., Yin, D. E., Moye, J., Spiegel, H., Gama, L., Gaudinski, M., & Capparelli, E. V. (2026). Model-based assessment of VRC07-523LS dosing in infants through population pharmacokinetic -pharmacodynamic modelling in adults and infants. Journal of Antimicrobial Chemotherapy. https://doi.org/10.1093/jac/dkaf449

Vancouver

Huynh D, Nikanjam M, Cunningham CK, McFarland EJ, Muresan P, Perlowski C, et al. Model-based assessment of VRC07-523LS dosing in infants through population pharmacokinetic -pharmacodynamic modelling in adults and infants. Journal of Antimicrobial Chemotherapy. 2026. doi:10.1093/jac/dkaf449

BibTeX
@article{Huynh2026,
  author = {Huynh, Dustin and Nikanjam, Mina and Cunningham, Coleen K and McFarland, Elizabeth J and Muresan, Petronella and Perlowski, Charlotte and Yin, Dwight E and Moye, Jack and Spiegel, Hans and Gama, Lucio and Gaudinski, Martin and Capparelli, Edmund V},
  title = {Model-based assessment of VRC07-523LS dosing in infants through population pharmacokinetic -pharmacodynamic modelling in adults and infants},
  journal = {Journal of Antimicrobial Chemotherapy},
  year = {2026},
  doi = {10.1093/jac/dkaf449}
}
Kostenlos starten →